The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study

• Published in: European heart journal Vol. 38; no. 44; pp. 3308 - 3317
• Main Authors: Schmieder, Roland E, Wagner, Frank, Mayr, Michael, Delles, Christian, Ott, Christian, Keicher, Christian, Hrabak-Paar, Maja, Heye, Tobias, Aichner, Solveig, Khder, Yasser, Yates, Denise, Albrecht, Diego, Langenickel, Thomas, Freyhardt, Patrick, Janka, Rolf, Bremerich, Jens
• Format: Journal Article
• Language: English
• Published: England 21.11.2017
• Subjects: Aminobutyrates - therapeutic use; Angiotensin Receptor Antagonists - therapeutic use; Antihypertensive Agents - therapeutic use; Aorta - drug effects; Aorta, Thoracic - drug effects; Biphenyl Compounds; Blood Pressure - drug effects; Double-Blind Method; Drug Combinations; Essential Hypertension - drug therapy; Essential Hypertension - physiopathology; Female; Heart Failure - physiopathology; Heart Failure - prevention & control; Humans; Hypertrophy, Left Ventricular - physiopathology; Hypertrophy, Left Ventricular - prevention & control; Imidazoles - therapeutic use; Magnetic Resonance Angiography; Male; Medication Adherence; Middle Aged; Neprilysin; Tetrazoles - therapeutic use; Valsartan; Vascular Stiffness - drug effects; Ventricular Remodeling - drug effects; Heart failure; Hypertension; Neprilysin; Arterial stiffness; Angiotensin; Left ventricular hypertrophy

Progressive aortic stiffening eventually leads to left ventricular (LV) hypertrophy and heart failure if left untreated. Anti-hypertensive agents have been shown to reverse this to some extent. The effects of sacubitril/valsartan (LCZ696), a dual-action angiotensin receptor blocker (ARB), and nepril...